Webcast Information: A live webcast of the presentation will be available via phone on 800-954-0621 and https://cc.callinfo.com/r/1ndy5w8zvlql0&eom. A replay will be available via www.anavex.com and will be accessible for a limited time following the presentation. About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 ( blarcamesine ), recently completed a successful Phase 2a clinical trial for Alzheimer's disease. ANAVEX®2-73 ( blarcamesine ) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors.